Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)

NCT06022757 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma
Squamous Cell Carcinoma of Head and Neck
Urothelial Carcinoma
Prostate Cancer
Small-cell Lung Cancer
Non-small Cell Lung Cancer
Cervical Cancer
Other Solid Tumors

Interventions

DRUG: XNW5004
DRUG: KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection

Sponsor

Evopoint Biosciences Inc.

Collaborators

[object Object]